MedTrace Logo

RENEW-SHCS: Safety and Immunogenicity of a Recombinant HIV Env Protein Vaccine in ARV-treated Adults Living With HIV in the SHCS

NCT07769983 · Status: ENROLLING_BY_INVITATION · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-08-18

No results posted yet for this study

Summary

A vaccine trial in which people with HIV-1 participating in the Swiss HIV Cohort Study will receive a HIV-specific vaccine to stimulate antibodies against HIV while continuing their standard antiretroviral therapy

Conditions

  • People Living With HIV
  • Antibody Response

Interventions

BIOLOGICAL

The Patients will all receive a vaccination with a recombinant HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 vaccine, adjuvanted,.

The vaccination with the HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 will be administered on Day 0 in selected PLWH with and without prior broadly neutralizing HIV-1 antibody activity.

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Huldrych Günthard, Prof. Dr. med. · University of Zurich, Universitiy Hospital Zurich

  • Alexandra Trkola, Prof. Dr. · University of Zurich

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-27
Primary Completion
2028-01-31
Completion
2028-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07769983 on ClinicalTrials.gov